Trials / Completed
CompletedNCT02526784
A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer
A Multi-Centre, Open-Label, Randomised Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to compare the severity of ISRs (Injection Site Reactions) following degarelix subcutaneous (s.c.) administrations with two different injection techniques and intramuscular (i.m.) administration in patients with hormone dependent prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | degarelix |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2017-05-01
- Completion
- 2017-06-01
- First posted
- 2015-08-18
- Last updated
- 2017-07-05
Locations
3 sites across 3 countries: Finland, France, Germany
Source: ClinicalTrials.gov record NCT02526784. Inclusion in this directory is not an endorsement.